Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
27.12.24 | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 27.12.2024 | 1.017 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 27.12.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 27.12.2024ISIN NameCA33812R1091 FISSION... ► Artikel lesen | |
16.12.24 | Nasdaq Stockholm AB: Delisting of Cyxone AB from Nasdaq First North Growth Market | 137 | GlobeNewswire | On December 9, 2024, Cyxone AB was declared bankrupt by Malmö District Court.
According to item 8.2.7 of the Nasdaq First North Growth Market Rulebook, the exchange may decide to delist the financial... ► Artikel lesen | |
06.12.24 | XFRA 4CX: AUSSETZUNG/SUSPENSION | 160 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCYXONE AB SK-,75... ► Artikel lesen | |
12.11.24 | Nasdaq Stockholm AB: Cyxone AB receives observation status | 212 | GlobeNewswire | On November 8, 2024, Cyxone AB (the "Company") disclosed a press release with
information on the Company's financial situation.
The rules of Nasdaq First North Growth Market state that an issuer can... ► Artikel lesen | |
CYXONE Aktie jetzt für 0€ handeln | |||||
08.11.24 | Nasdaq Stockholm AB: Lift of Suspension in Cyxone AB at FNSE | 214 | GlobeNewswire | Lifting of Suspension
At Trading Venue FNSE
Issuer: Cyxone AB, LEI: 54930034OH16ROAY4K87
--------------------------------------------------------------------------------
Instruments:... ► Artikel lesen | |
26.08.24 | Cyxone AB announces last day of trading in BTA | 4 | Cision News | ||
16.08.24 | Cyxone AB publishes outcome of rights issue | 9 | Cision News | ||
01.08.24 | The subscription period in Cyxone's rights issue starts today | 15 | Cision News | ||
31.07.24 | Cyxone AB publishes investment memorandum | 1 | Cision News | ||
26.07.24 | XFRA CAPITAL ADJUSTMENT INFORMATION - 26.07.2024 | 303 | Xetra Newsboard | Das Instrument 1NN ES0105251005 NEINOR HOMES SA EO 8,21 EQUITY wird cum Kapitalmassnahme gehandelt am 26.07.2024 und ex Kapitalmassnahme am 29.07.2024 The instrument 1NN ES0105251005 NEINOR HOMES SA... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 112,80 | +0,18 % | Fast 200 % Kurspotenzial! Nel ASA, Evotec, BioNTech, Medigene Aktien! | Die Aktie von Medigene hat mit dem Turnaround begonnen. Neben positiven Patent-News aus Japan für das Krebs-Testis-Antigen MAGE-A4 treibt eine Kaufempfehlung das Wertpapier. So sehen Analysten mehr... ► Artikel lesen | |
VALNEVA | 2,262 | -0,18 % | Valneva: Hohe Immunantwort durch Chikungunya-Impfstoff | Valneva hat neue Phase-3-Daten für den Chikungunya-Impfstoff IXCHIQ veröffentlicht, die eine anhaltend hohe Immunantwort bei Jugendlichen bestätigen. Ein Jahr nach der einmaligen Impfung zeigten Studienteilnehmer... ► Artikel lesen | |
NOVAVAX | 8,689 | -1,05 % | Schock-News für Novavax Anleger vor dem Wochenende: So müssen Sie heute noch auf diese Sondermeldung reagieren! | ||
BAVARIAN NORDIC | 26,560 | -0,52 % | Bavarian Nordic Aktie: Sondermeldung sorgt für starke Verunsicherung. Das ist der Grund und so müssen Anleger heute handeln! | ||
COSCIENS BIOPHARMA | 2,560 | +2,40 % | COSCIENS Biopharma Inc. Provides Corporate Update and Highlights Pipeline Prioritization | Company leveraging core competencies to develop and commercialize natural-based products to improve health and wellness Streamlined efficiencies and cost cutting measures taken to refine operations... ► Artikel lesen | |
PHIO PHARMACEUTICALS | 2,215 | -5,34 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series | Marlborough, Massachusetts--(Newsfile Corp. - January 22, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA... ► Artikel lesen | |
ORAGENICS | 0,295 | +3,80 % | Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO | SARASOTA, Fla., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for brain-related health conditions, today provided... ► Artikel lesen | |
LEXICON PHARMACEUTICALS | 0,967 | +2,60 % | Lexicon Pharmaceuticals, Inc.: Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain | ||
CSTONE PHARMACEUTICALS | 0,290 | 0,00 % | CStone Pharmaceuticals: Encouraging Efficacy and Safety: CStone Presents Latest Clinical Data on CS5001 for Advanced Lymphoma at the 66th ASH Annual Meeting | CS5001 is so far the first anti-ROR1 ADC known to show clinical anti-tumor activity in both solid tumors and lymphomas. The data presented at ASH highlighted the... ► Artikel lesen | |
OUTLOOK THERAPEUTICS | 1,820 | -3,70 % | Outlook Therapeutics, Inc. - 10-K/A, Annual Report | ||
NANOSPHERE HEALTH SCIENCES | 0,023 | -73,71 % | Nanosphere Health Sciences Inc (2): Nanosphere Health Sciences to hold AGM Dec. 13 | ||
GENSCRIPT BIOTECH | 1,270 | 0,00 % | GENSCRIPT BIO (01548): VOLUNTARY ANNOUNCEMENT: LEGEND BIOTECH ANNOUNCES PRELIMINARY SALES FOR CARVYKTI FOR THE QUARTER ENDED 31 DECEMBER 2024 | ||
KRYSTAL BIOTECH | 148,55 | +0,64 % | (KRYS) - Analyzing Krystal Biotech's Short Interest | ||
VERVE THERAPEUTICS | 7,900 | -1,13 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on December 31,... ► Artikel lesen | |
LEAP THERAPEUTICS | 2,060 | -2,83 % | Leap Therapeutics, Inc.: Leap Therapeutics Reports Third Quarter 2024 Financial Results | CAMBRIDGE, Mass., Nov. 13, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology... ► Artikel lesen |